We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App




D-Dimer and Thrombosis Risk in Adult Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 07 Sep 2022
Print article
Image: The STA R MAX is a hemostasis analyzer for high-volume and reference laboratories performing routine and specialty assays (Photo courtesy of Stago)
Image: The STA R MAX is a hemostasis analyzer for high-volume and reference laboratories performing routine and specialty assays (Photo courtesy of Stago)

D-dimer is a marker of fibrinolysis harkening the presence of or risk for thrombosis, and it has been found to be a powerful predictor of thrombosis in solid cancers and acute myeloid leukemia (AML).

Patients with acute lymphoblastic leukemia (ALL) are at increased risk of thrombotic and/or bleeding events during early chemotherapy, especially when receiving asparaginase. Rates of venous thromboembolism (VTE) in ALL vary across studies, ranging from 1% to 36%, with the majority of studies reporting rates in the 5% to 20% range over a 1- to 3-year follow-up period.

A team of medical scientists led by The University of Chicago (Chicago, IL, USA) team identified 61 consecutive adult patients with newly diagnosed ALL from a single center between January 2008 and March 2020. They gathered demographic characteristics, treatment regimens, initial biomarkers including D-dimer, and assessing occurrence of venous or arterial thrombosis and bleeding in the first 100 days after diagnosis (index). The median age overall was 36 years (range, 18-84 years), with 52% female.

The D-dimer assay is ordered routinely at diagnosis of ALL at The University of Chicago Medical Center as a plasma assay and performed using photometric immunoassay analysis on a STA R Max analyzer (Diagnostica Stago, Inc, Parsippany, NJ, USA) within six hours of blood draw. Patients were stratified into two groups according to index D-dimer level using a cutoff of ≥4 µg/mL fibrinogen equivalent units (FEU) (high) and <4 µg/mL (low to moderate) based on previous work examining D-dimer and thrombosis in AML and the cutoff used in the disseminated intravascular coagulation (DIC) score.

The investigators reported that in the study cohort of patients with ALL, of whom 17 (28%) had high (≥4 µg/mL FEU) D-dimer levels at index, and 44 (72%) had low to moderate (<4 µg/mL FEU) index D-dimer levels. The 100-day cumulative incidence (95% confidence interval [CI]) of venous or arterial thrombosis in patients with high D-dimer (≥4 µg/mL) was 52.9% (95% CI, 26.4-73.8) compared with 13.8% (95% CI, 5.5-25.7) in patients with low to moderate D-dimer (<4 µg/mL), corresponding with a hazard ratio of 5.04 (95% CI, 1.79-14.22). When testing for potential confounders in a series of bivariate logistic regression models, the association between D-dimer and thrombosis remained after adjusting for body mass index, age, sex, asparaginase treatment, disseminated intravascular coagulation score, initial platelet level, and ALL phenotype.

The authors concluded that D-dimer levels at ALL diagnosis were associated with venous or arterial thrombosis at 100 days. Future studies should include D-dimer collated with other known risk factors to build a risk assessment model for thrombosis in patients newly diagnosed with ALL. The study was published on September 1, 2022 in the journal Blood Advances.

Related Links:
The University of Chicago 
Diagnostica Stago 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.